Business Context and Reporting Period
This Form 8-K, dated January 30, 2004, reports unaudited pro forma financial information for SIGA Technologies, Inc. regarding its acquisition of substantially all assets of Plexus Vaccine Inc. on May 23, 2003. The pro forma statements present combined results for the nine months ended September 30, 2003, and the year ended December 31, 2002, as if the transaction had occurred on January 1, 2002.
Key Financial Metrics
Transaction Consideration: SIGA issued 1,950,000 shares of common stock and 190,950 options/warrants (exercise price $1.62) to acquire Plexus assets. The preliminary purchase price allocation totaled approximately $4,070,903.
Pro Forma Results (Nine Months Ended Sept 30, 2003):
- Total Revenues: $719,798
- Total Operating Expenses: $5,715,668
- Operating Loss: $(4,995,870)
- Net Loss: $(5,931,951)
- Loss Per Share (Basic/Diluted): $(0.38)
Pro Forma Results (Year Ended Dec 31, 2002):
- Total Revenues: $516,828
- Total Operating Expenses: $5,853,781
- Operating Loss: $(5,336,953)
- Net Loss: $(5,398,730)
- Loss Per Share (Basic/Diluted): $(0.44)
Intangible Assets Acquired:
- Acquired Technology: $2,191,000
- Contracts and Grants: $741,000
- Covenant Not to Compete: $707,000
- Goodwill: $898,334
Liquidity and Debt: The filing text does not provide specific values for cash balances, debt levels, or liquidity ratios in the pro forma statements.
Material Changes Versus Prior Period
The pro forma data reflects the consolidation of Plexus operations with SIGA. Compared to SIGA's historical standalone results for the nine months ended September 30, 2003, the combined entity shows:
- Revenue Increase: From $625,016 (SIGA historical) to $719,798 (Pro Forma Combined).
- Expense Increase: Operating expenses rose from $4,301,270 to $5,715,668 due to the inclusion of Plexus expenses and pro forma adjustments for amortization.
- Loss Increase: Net loss applicable to common shareholders increased from $(3,663,206) to $(5,931,951).
Pro forma adjustments included amortization of the covenant not to compete ($84,167) and acquired technology/contracts ($179,506) for the nine-month period.
Guidance, Outlook, and Risks
Management Commentary: The pro forma information is presented for illustrative purposes only. It is not necessarily indicative of operating results that would have been achieved if the acquisition occurred at the beginning of the periods, nor does it predict future results.
Limitations: The statements do not reflect potential cost savings or incremental costs resulting from the integration of SIGA and Plexus operations.
Valuation Methodologies: Intangible assets were valued using income approaches, including relief from royalty (3.0% royalty rate, 28.5% discount rate) for technology and excess earnings (26.0% discount rate) for contracts and covenants.
Investor Verification Checklist
- Verify the final allocation of the purchase price, as the current filing notes it is preliminary.
- Confirm the actual cash flow impact and liquidity position post-acquisition, as these are not detailed in the pro forma operations statement.
- Review the integration progress to assess if anticipated cost savings or synergies are being realized.
- Monitor the amortization schedules for the acquired intangible assets (technology, contracts, covenant) to understand future expense impacts.
- Check subsequent filings for updates on the status of the acquired patents and pending applications.